Nature Communications (Nov 2023)

CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade

  • Tomoko Yamamori Morita,
  • Jie Yu,
  • Yukie Kashima,
  • Ryo Kamata,
  • Gaku Yamamoto,
  • Tatsunori Minamide,
  • Chiaki Mashima,
  • Miyuki Yoshiya,
  • Yuta Sakae,
  • Toyohiro Yamauchi,
  • Yumi Hakozaki,
  • Shun-ichiro Kageyama,
  • Akito Nakamura,
  • Eric Lightcap,
  • Kosuke Tanaka,
  • Huifeng Niu,
  • Karuppiah Kannan,
  • Akihiro Ohashi

DOI
https://doi.org/10.1038/s41467-023-43274-3
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 21

Abstract

Read online

Abstract Serine/threonine kinase, cell division cycle 7 (CDC7) is critical for initiating DNA replication. TAK-931 is a specific CDC7 inhibitor, which is a next-generation replication stress (RS) inducer. This study preclinically investigates TAK-931 antitumor efficacy and immunity regulation. TAK-931 induce RS, generating senescence-like aneuploid cells, which highly expressed inflammatory cytokines and chemokines (senescence-associated secretory phenotype, SASP). In vivo multilayer-omics analyses in gene expression panel, immune panel, immunohistochemistry, RNA sequencing, and single-cell RNA sequencing reveal that the RS-mediated aneuploid cells generated by TAK-931 intensively activate inflammatory-related and senescence-associated pathways, resulting in accumulation of tumor-infiltrating immune cells and potent antitumor immunity and efficacy. Finally, the combination of TAK-931 and immune checkpoint inhibitors profoundly enhance antiproliferative activities. These findings suggest that TAK-931 has therapeutic antitumor properties and improved clinical benefits in combination with conventional immunotherapy.